– Phase 1a clinical trial of OLX-07010, a novel oral, small molecule inhibitor of tau self-association, expected to start in the coming months –

WHITE PLAINS, NY, USA I November 30, 2022 I Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer’s Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings in November 2022.

“With millions of Americans suffering from Alzheimer’s disease and other neurodegenerative disorders, patients are desperate for safer, accessible and more effective treatment options,” said James Moe, Ph.D., MBA, CEO and Head of Discovery and Strategy at Oligomerix. “As an orally available therapy, OLX-07010 has the potential to greatly improve patient outcomes and reduce socioeconomic burden.”

At the meetings, the company presented data from IND-enabling studies demonstrating the safety and pharmacokinetic profile of OLX-07010 in in vitro and in vivo preclinical studies. In multiple animal species, OLX-07010, a novel small molecule inhibitor of tau self-association, demonstrated good oral bioavailability, with no significant adverse effects reported at the highest dose levels tested. Furthermore, in in vitro studies, OLX-07010 demonstrated a low potential for interactions with other commonly prescribed medicines when administered at the anticipated efficacious dose. These results further support OLX-07010’s potential as a clinical candidate for Alzheimer’s disease and other dementias where tau plays a significant role.

“The highly-differentiated mechanism of action and robust preclinical profile of OLX-07010 validates its disease-modifying potential to treat tau-related neurological diseases,” said William Erhardt, M.D., President and Head of Development at Oligomerix. “We have been working closely with FDA and our funder, the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to finalize our protocol for our first-in-human study, and we look forward to initiating our Phase 1a study of OLX-07010 in the coming months.”

About OLX-07010

OLX-07010 is an oral, small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade, a process believed to be implicated in the development of Alzheimer’s disease and other neurodegenerative disorders. Oligomerix’s lead candidate has demonstrated efficacy in multiple animal models of tau-mediated neurodegeneration. Phase 1a first-in-human clinical studies are expected to begin in the near term.

About Oligomerix, Inc.

Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies, such as progressive supranuclear palsy and frontotemporal dementia, to Alzheimer’s disease.

Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are potentially easy to administer and cost-effective. Oligomerix’s portfolio of compounds is expected to provide a potentially lower-cost treatment alternative or complement the newly emerging high-cost therapeutic options such as monoclonal antibody products.

Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. Follow Oligomerix on LinkedIn.

Oligomerix is seeking strategic partners and investors to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit our website at https://oligomerix.com/.

SOURCE: Oligomerix